When Pfizer marketed the pain killers Bextra and Celebrex, they conveniently
failed to inform the FDA and public of studies showing that the drugs
were linked to heart attacks, strokes, blood clots and a life-threatening
skin diseases known as Stevens Johnson Syndrome (SJS) and Toxic Epidermal
Necrosis (TENS). While our frm was championing litigation for injured
plaintiffs, sharholders launched litigation based on the decreased value
of Pfizer's stock. Five corporate executives who are alleged to have
been aware of this damging information but sis not warn shareholders,
filed legal action directly naming the executives. There has been a torutured
legal history of whthe the executives were in fact involved and, if so,
they could be named individually. A federal judge in Manhattan (Pfizer's
corporate headquarters) just confirmed in a ruling that there was enough
evidence alleged in order to proceed, in particular pointing to the employees
roles in co-promting the drugs with then co-promoter, Pharmacia.
